The new science and business of oral biologics

Biologics are built for precision. The gastrointestinal tract is built for demolition. Between stomach acid, digestive enzymes, and the physical barricade of the intestinal wall, most large molecules do not merely struggle to get absorbed. They get dismantled.

That is why the “oral biologics” dream has always been more than a convenience play. It is a wager that a notoriously unforgiving system can be bent, briefly, locally, and safely, without causing collateral problems that regulators, patients, and payers will not tolerate.

In the last few years, the conversation has sharpened. The question is no longer whether anyone can get a peptide into the bloodstream from a pill. It is whether the approaches can scale beyond a few exceptional products, into something repeatable across indications, dose ranges, and patient populations.